Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers.

IF 6.9 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Rui-Xue Xia, Pei-Chen Zou, Jun-Ting Xie, Ya-Bin Tang, Miao-Miao Gong, Fu Fan, Ayinazhaer Aihemaiti, Yu-Qing Liu, Ying Shen, Bin-Bing S Zhou, Liang Zhu, Hui-Min Lei
{"title":"Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers.","authors":"Rui-Xue Xia, Pei-Chen Zou, Jun-Ting Xie, Ya-Bin Tang, Miao-Miao Gong, Fu Fan, Ayinazhaer Aihemaiti, Yu-Qing Liu, Ying Shen, Bin-Bing S Zhou, Liang Zhu, Hui-Min Lei","doi":"10.1038/s41401-024-01409-2","DOIUrl":null,"url":null,"abstract":"<p><p>RAS is the most frequently mutated oncoprotein for cancer driving. Understanding of RAS biology and discovery of druggable lynchpins in RAS pathway is a prerequisite for targeted therapy of RAS-mutant cancers. The recent identification of KRAS<sup>G12C</sup> inhibitor breaks the \"undruggable\" curse on RAS and has changed the therapy paradigm of KRAS-mutant cancers. However, KRAS mutations, let alone KRAS<sup>G12C</sup> mutation, account for only part of RAS-mutated cancers. Targeted therapies for cancers harboring other RAS mutations remain the urgent need. In this study we explored the pivotal regulatory molecules that allow for broad inhibition of RAS mutants. By comparing the expression levels of nucleotide pyrophosphatase (NPPS) in a panel of cell lines and the functional consequence of increased NPPS expression in RAS-mutant cells, we demonstrated that cancer cells with various kinds of RAS mutations depended on NPPS for growth and survival, and that this dependence conferred a vulnerability of RAS-mutant cancer to treatment of NPPS inhibition. RAS-mutant cells, compared with RAS-wildtype cells, bored and required an upregulation of NPPS. Transcriptomics and metabolomics analyses revealed a NPPS-dependent hyperglycolysis in RAS-mutant cells. We demonstrated that NPPS promoted glucose-derived glycolytic intermediates in RAS-mutant cells by enhancing its interaction with hexokinase 1 (HK1), the enzyme catalyzing the first committed step of glycolysis. Pharmacological inhibition of NPPS-HK1 axis using NPPS inhibitor Enpp-1-IN-1 or HK1 inhibitor 2-deoxyglucose (2-DG), or genetic interfere with NPPS suppressed RAS-mutant cancers in vitro and in vivo. In conclusion, this study reveals an unrecognized mechanism and druggable lynchpin for modulation of pan-mutant-RAS pathway, proposing a new potential therapeutic approach for treating RAS-mutant cancers.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-024-01409-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

RAS is the most frequently mutated oncoprotein for cancer driving. Understanding of RAS biology and discovery of druggable lynchpins in RAS pathway is a prerequisite for targeted therapy of RAS-mutant cancers. The recent identification of KRASG12C inhibitor breaks the "undruggable" curse on RAS and has changed the therapy paradigm of KRAS-mutant cancers. However, KRAS mutations, let alone KRASG12C mutation, account for only part of RAS-mutated cancers. Targeted therapies for cancers harboring other RAS mutations remain the urgent need. In this study we explored the pivotal regulatory molecules that allow for broad inhibition of RAS mutants. By comparing the expression levels of nucleotide pyrophosphatase (NPPS) in a panel of cell lines and the functional consequence of increased NPPS expression in RAS-mutant cells, we demonstrated that cancer cells with various kinds of RAS mutations depended on NPPS for growth and survival, and that this dependence conferred a vulnerability of RAS-mutant cancer to treatment of NPPS inhibition. RAS-mutant cells, compared with RAS-wildtype cells, bored and required an upregulation of NPPS. Transcriptomics and metabolomics analyses revealed a NPPS-dependent hyperglycolysis in RAS-mutant cells. We demonstrated that NPPS promoted glucose-derived glycolytic intermediates in RAS-mutant cells by enhancing its interaction with hexokinase 1 (HK1), the enzyme catalyzing the first committed step of glycolysis. Pharmacological inhibition of NPPS-HK1 axis using NPPS inhibitor Enpp-1-IN-1 or HK1 inhibitor 2-deoxyglucose (2-DG), or genetic interfere with NPPS suppressed RAS-mutant cancers in vitro and in vivo. In conclusion, this study reveals an unrecognized mechanism and druggable lynchpin for modulation of pan-mutant-RAS pathway, proposing a new potential therapeutic approach for treating RAS-mutant cancers.

NPPS 的依赖性为 RAS 突变癌症提供了可瞄准的弱点。
RAS 是最常发生突变的致癌蛋白。了解 RAS 的生物学特性并发现 RAS 通路中可药物治疗的关键环节,是对 RAS 突变癌症进行靶向治疗的先决条件。最近发现的 KRASG12C 抑制剂打破了 RAS "不可药用 "的魔咒,改变了 KRAS 突变癌症的治疗模式。然而,KRAS突变(更不用说KRASG12C突变)只占RAS突变癌症的一部分。针对携带其他 RAS 突变的癌症的靶向疗法仍是当务之急。在这项研究中,我们探索了能够广泛抑制 RAS 突变体的关键调控分子。通过比较核苷酸焦磷酸酶(NPPS)在一组细胞系中的表达水平以及 NPPS 在 RAS 突变细胞中表达增加的功能性后果,我们证明了具有各种 RAS 突变的癌细胞的生长和存活依赖于 NPPS,而这种依赖性使 RAS 突变癌症易受 NPPS 抑制治疗的影响。与RAS野生型细胞相比,RAS突变细胞对NPPS的上调感到厌烦和需要。转录组学和代谢组学分析表明,RAS 突变细胞中存在依赖 NPPS 的高糖酵解。我们证明,NPPS 通过加强与催化糖酵解第一步的酶 hexokinase 1(HK1)的相互作用,促进了 RAS 突变细胞中葡萄糖衍生的糖酵解中间产物。使用 NPPS 抑制剂 Enpp-1-IN-1 或 HK1 抑制剂 2-脱氧葡萄糖(2-DG)对 NPPS-HK1 轴进行药理抑制,或对 NPPS 进行基因干扰,可抑制体外和体内的 RAS 突变癌症。总之,这项研究揭示了一种尚未认识到的泛互补-RAS通路调节机制和可药物治疗的关键,为治疗RAS突变癌症提出了一种新的潜在治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmacologica Sinica
Acta Pharmacologica Sinica 医学-化学综合
CiteScore
15.10
自引率
2.40%
发文量
4365
审稿时长
2 months
期刊介绍: APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信